Kamada Confirms KedRAB Supply As U.S. Rabies Exposures Increase
Kamada Ltd. (KMDA, KMDA.TA) confirmed sufficient inventory and capacity to meet increased U.S. demand for its KedRAB product, following a CDC advisory on rising rabies exposures. KedRAB is one of two FDA-approved anti-rabies treatments. The company cited its supply chain and partnerships as supportive factors. Kamada's stock is up 0.92% at ILA 2,517.
How this was made
The 30-second read
Why it matters
Kamada's inventory assurance addresses immediate market concerns but does not signal a major growth catalyst.
Market read
The announcement may stabilize KMDA's share price amid heightened demand concerns.
What to watch
Potential regulatory changes or competitor capacity expansions could alter the supply landscape.
Background
CDC reported a year‑over‑year rise in human rabies exposures, increasing demand for anti‑rabies immunoglobulins.
Market effects
May reassure the broader plasma‑derived therapeutics sector about supply stability.
U.S. rabies immunoglobulin market could see steadier pricing.
Limited to niche biotech and specialty pharma investors.
Counterpoint
If demand spikes further, current inventory may still be insufficient, keeping upside limited.
Key entities
- CompanyKamada Ltd.
Manufacturer of KedRAB, a human rabies immune globulin.
- PartnerKedrion Biopharma Inc.
Commercialization partner for KedRAB in the U.S.
